title: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly or poor-performance status patients with advanced breast cancer.
  
  
  METHODS
  Forty-one patients with advanced breast cancer who were either over the age of 65 or considered to be poor candidates for combination chemotherapy received docetaxel 36 mg/m2 weekly for 6 consecutive weeks, followed by 2 weeks without treatment. The median age of patients in this trial was 74 years, and 73% of patients had one or more visceral sites of metastases. Seventy-five percent of patients received weekly docetaxel as first-line treatment for metastatic breast cancer, and the other 25% received it as second-line treatment. Thirty-six patients were assessable for efficacy, and all patients were assessed for toxicity.
  
  
  RESULTS
  A total of 448 doses of weekly docetaxel were administered to 41 patients. Thirteen patients (36%) had objective responses to treatment, and an additional 13 patients (36%) had stable disease or minor response. Median time to progression for responding and stable patients was 7 months (range, 3 to 27 months). Median survival for the entire group was 13 months, with 1- and 2-year actuarial survival rates of 61% and 29%, respectively. Severe neutropenia occurred in only 0.4% of courses, and no other hematologic toxicity was observed. Grade 3/4 fatigue was the most common toxicity, occurring in 20% of patients.
  
  
  CONCLUSIONS
  Weekly docetaxel therapy is active and well tolerated by elderly and/or poor-performance status patients with advanced breast cancer. This treatment can be administered with minimal myelosuppression. Weekly docetaxel provides an additional option for treatment in this difficult subgroup of patients with metastatic breast cancer. Well-tolerated combination regimens containing weekly docetaxel merit evaluation for this patient population.
authors.affiliation: Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA. jhainsworth@tnonc.com
authors.forename: J D
authors.initials: JD
authors.lastname: Hainsworth
authors.forename: H A
authors.initials: HA
authors.lastname: Burris
authors.forename: D A
authors.initials: DA
authors.lastname: Yardley
authors.forename: J E
authors.initials: JE
authors.lastname: Bradof
authors.forename: M
authors.initials: M
authors.lastname: Grimaldi
authors.forename: L A
authors.initials: LA
authors.lastname: Kalman
authors.forename: T
authors.initials: T
authors.lastname: Sullivan
authors.forename: M
authors.initials: M
authors.lastname: Baker
authors.forename: J B
authors.initials: JB
authors.lastname: Erland
authors.forename: F A
authors.initials: FA
authors.lastname: Greco
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015996:Survival Rate; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel